Compare Fox Corp Class A (FOXA) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Merck & Co., Inc. — how do they compare? Fox Corp Class A trades at $63.88 (market cap $25.36B), while Merck & Co., Inc. trades at $142.17 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 13.9× Fox Corp Class A's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Merck & Co., Inc. for 98 Days on average.
| FOXA | MRK | |
|---|---|---|
Market Cap | $25.36B | $351.28B |
Volume | 2,566,954 | 7,969,665 |
Sector | Media | Health |
52-Week High | $76.11 | $156.43 |
52-Week Low | $48.79 | $82.49 |
Typical Hold Time | 34 Days | 98 Days |
Enterprise Value | $28.72B | $398.04B |
Dividend Yield | 0.91% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.70, up 1.0% today, with a bearish technical signal but strong fundamentals including a P/E of 16.55 and net income margin of 9.84%. Recent earnings beats and a consensus analyst price target of $72.00 suggest upside potential, though the pending Roku acquisition faces DOJ scrutiny, adding regulatory risk. Cash flow improved in 2025, but a projected net cash outflow in 2026 warrants monitoring.
The outlook is mixed: solid profitability and analyst support contrast with technical weakness and acquisition uncertainty. Investors may find value if the Roku deal proceeds smoothly, but regulatory delays or integration challenges pose significant downside risks to near-term performance.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
